A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...

Pfizer already makes big revenues from its breast cancer drug Ibrance ... therapy alone in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early-stage ...

several generic drug companies are poised for growth. Though generic drugs represent more than 90% of dispensed prescriptions, generic drug manufacturers continue to face pressure from drug ...

FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys ...

According to InvestingPro data, the company has demonstrated strong momentum with revenue growth of 12.32% over the last twelve months. The company's focus on generic drugs, biosimilars ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

These everyday foods contain ingredients linked to cancer by the FDA, yet they remain on store shelves. Find out what they ...

Low-fat diets are problematic, says world-renowned internist and regenerative physician Michael Aziz, MD, author of the ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

If you’ve been on the internet recently, you’ve likely encountered Bryan Johnson’s meticulously optimized, data-driven quest ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...